Han Woong Lee,Jung-Min Choi,Byoung Chul Cho,Yu-Ra Choi,Ji-Young Jang,Hye Ryun Kim
申请号：
US15458676
公开号：
US10480032B2
申请日:
2017.03.14
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present disclosure relates to a novel use of EI24, and provides a novel use of EI24 involved in the improvement of EGFR-TKI drug resistance by inhibiting IGF-1R signaling. According to the present disclosure, the presence or absence of resistance to anti-cancer drugs may be determined by detecting an expression level of EI24. In addition, resistance to anti-cancer drugs may be inhibited, delayed, or improved using EI24 or an activating agent thereof. Moreover, by regulating a pathway of EI24-mediated resistance to anti-cancer drugs, the efficacy of existing anti-cancer drugs may be enhanced, and resistance to anti-cancer drugs may be inhibited, delayed, or improved.
